Abstract 517P
Background
The prognostic predictive value of breast cancer susceptibility gene 1 (BRCA1) for non-small-cell lung cancer (NSCLC) remains controversial. This study aimed to determine the prognostic effect of BRCA1 on NSCLC survival using meta-bioinformatic analysis.
Methods
Candidate articles were identified from PubMed, Embase, Cochrane Library, and Web of Science databases. Effect measures generated were the pooled hazard ratio (HR) and 95% confidence interval (CI). Cox regression model was performed in an independent dataset from TCGA to validate the accuracy of our meta-analysis.
Results
A total of 2462 patients from 15 studies of acceptable quality were included. No significant differences in overall survival (OS)/cancer-specific survival (CSS) (HR = 1.38, 95% CI: 0.95-2.00, P = 0.094) or progression-free survival (PFS)/disease-free survival (DFS)/relapse-free survival (RFS) (HR = 1.28, 95% CI: 0.82-2.00, P = 0.284) were observed between patients with high- and low-expression of BRCA1. However, patients with lung adenocarcinoma (LUAD) and increased BRCA1 expression had markedly poorer OS/CSS (HR = 1.78, 95% CI: 1.05-3.03, P = 0.032) than those with reduced BRCA1. Bioinformatics analysis also indicated that BRCA1 overexpression was independently correlated with decreased OS in LUAD. Moreover, patients with high BRCA1 were more likely to suffer from lymph node metastasis than those with low BRCA1.
Conclusions
Elevated BRCA1 expression may be a novel biomarker of poor OS for patients with LUAD.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract